Publicaciones en colaboración con investigadores/as de Clínica Universitaria de Navarra (21)

2023

  1. Preferential expression of SCN1A in GABAergic neurons improves survival and epileptic phenotype in a mouse model of Dravet syndrome

    Journal of Molecular Medicine, Vol. 101, Núm. 12, pp. 1587-1601

2022

  1. Oncolytic DNX-2401 Virus for Pediatric Diffuse Intrinsic Pontine Glioma

    New England Journal of Medicine, Vol. 386, Núm. 26, pp. 2471-2481

2021

  1. Author Correction: Epilepsy and neuropsychiatric comorbidities in mice carrying a recurrent Dravet syndrome SCN1A missense mutation (Scientific Reports, (2019), 9, 1, (14172), 10.1038/s41598-019-50627-w)

    Scientific Reports

  2. Transfer of SCN1A to the brain of adolescent mouse model of Dravet syndrome improves epileptic, motor, and behavioral manifestations

    Molecular Therapy - Nucleic Acids, Vol. 25, pp. 585-602

2019

  1. Epilepsy and neuropsychiatric comorbidities in mice carrying a recurrent Dravet syndrome SCN1A missense mutation

    Scientific Reports, Vol. 9, Núm. 1

2017

  1. X-box Binding Protein 1 Regulates Unfolded Protein, Acute-Phase, and DNA Damage Responses During Regeneration of Mouse Liver

    Gastroenterology, Vol. 152, Núm. 5, pp. 1203-1216.e15

2016

  1. Capsid-deficient alphaviruses generate propagative infectious microvesicles at the plasma membrane

    Cellular and Molecular Life Sciences, Vol. 73, Núm. 20, pp. 3897-3916

  2. Long-term metabolic correction of Wilson's disease in a murine model by gene therapy

    Journal of Hepatology, Vol. 64, Núm. 2, pp. 419-426

2015

  1. Enhanced therapeutic effect using sequential administration of antigenically distinct oncolytic viruses expressing oncostatin M in a Syrian hamster orthotopic pancreatic cancer model

    Molecular Cancer, Vol. 14, Núm. 1

2013

  1. Cytokines for the treatment of gastrointestinal cancers: Clinical experience and new perspectives

    Expert Opinion on Investigational Drugs, Vol. 22, Núm. 7, pp. 827-841

2012

  1. Evaluation of monocytes as carriers for armed oncolytic adenoviruses in murine and Syrian hamster models of cancer

    Human Gene Therapy, Vol. 23, Núm. 12, pp. 1258-1268

2011

  1. Gene therapy of liver cancer: An update

    Journal Africain du Cancer, Vol. 3, Núm. 3, pp. 180-192

  2. Oxaliplatin in combination with liver-specific expression of interleukin 12 reduces the immunosuppressive microenvironment of tumours and eradicates metastatic colorectal cancer in mice

    Gut, Vol. 60, Núm. 3, pp. 341-349

  3. Self-inactivating helper virus for the production of high-capacity adenoviral vectors

    Gene Therapy, Vol. 18, Núm. 11, pp. 1025-1033

2009

  1. Deletion of the E3-6.7K/gp19K region reduces the persistence of wild-type adenovirus in a permissive tumor model in Syrian hamsters

    Cancer Gene Therapy, Vol. 16, Núm. 9, pp. 703-712

  2. Evaluation of bioluminescent imaging for noninvasive monitoring of colorectal cancer progression in the liver and its response to immunogene therapy

    Molecular Cancer, Vol. 8

2008

  1. Interleukin-12 inhibits liver-specific drug-inducible systems in vivo

    Gene Therapy, Vol. 15, Núm. 4, pp. 277-288

2007

  1. Gene therapy of liver cancer

    Annals of Hepatology, Vol. 6, Núm. 1, pp. 5-14

2006

  1. Recombinant Adenoviral Vectors Turn on the Type I Interferon System without Inhibition of Transgene Expression and Viral Replication

    Molecular Therapy, Vol. 14, Núm. 1, pp. 129-138

2005

  1. In utero gene therapy: Current challenges and perspectives

    Molecular Therapy, Vol. 11, Núm. 5, pp. 661-676